• SENSEX 83,919.71
    897.96 (+1.08%)
  • BANKNIFTY 64,635.20
    1,572.20 (+2.49%)
Back

Results - Announcements

Ipca Laboratories Ltd consolidated sales up 4.37% on year in Q3FY2026
06-Nov-2026, 10:55

Ipca Laboratories Ltd share price softened by 1.18% to Rs 1949.8 after the company's net profit slipped by 7.40% to Rs 391.54 crore, while revenue from operations slightly gained 4.37% to Rs 2909.94 crore in Q3FY26 over Q2FY26.


The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.82 lakh crore, rising 5.09%. It has improved by 2.18% over last one week and ticked higher by 2.72% in last one month while the market capitalization of Ipca Laboratories Ltd has marginally improved by 1.15% and 12.26% in the same period respectively.


Profit before tax (PBT) of Ipca Laboratories Ltd stood at Rs 547.17 crore in Q3 FY26, surging by 39.73% year-on-year, and slipping 4.35% quarter-on-quarter. EBITDA came in at Rs 648 crore, jumping 25.41% YoY and gaining 0.65% sequentially.


Total expenses saw a slight increase of 5.45% to Rs 2350.97 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 746.67 crore, advancing by 17.01% YoY, while employee benefits expense was at Rs 617.43 crore, inching up 2.64% YoY.


For the TTM ended FY26, revenue from operations posted a slight growth of 7.91% to Rs 9646.33 crore, while net profit surged by 51.28% to Rs 1191.37 crore, compared to previous TTM. EBITDA jumped by 165264% to Rs 1804.11 crore, and PBT surged 39.02% to Rs 1572.52 crore compared to previous TTM.


The company's consolidated net cash flow from operating activities stood at Rs 1141.97 crore in FY26, as against Rs 1321.32 crore in FY25.


Ipca Laboratories Ltd soared by 49.71% in last one year, significantly outperforming the benchmark BSE Sensex which has eased by 4.80% during the same period.